1-[(叔丁氧基)羰基]-3-甲氧基氮杂环丁烷-3-羧酸 | 1780970-70-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 中文名称: 1-[(叔丁氧基)羰基]-3-甲氧基氮杂环丁烷-3-羧酸
• 英文名称: 1-(tert-butoxycarbonyl)-3-methoxyazetidine-3-carboxylic acid
• 英文别名: 1-[(Tert-butoxy)carbonyl]-3-methoxyazetidine-3-carboxylic acid；3-methoxy-1-[(2-methylpropan-2-yl)oxycarbonyl]azetidine-3-carboxylic acid
• CAS: 1780970-70-8
• 化学式: C₁₀H₁₇NO₅
• 分子量: 231.249
• InChiKey: RDCWOPRWTAQCRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-[(叔丁氧基)羰基]-3-甲氧基氮杂环丁烷-3-羧酸 在 甲酸 、 2-羟基吡啶-N-氧化物 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 19.25h， 生成 (S)-N-(1-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-3-methoxy-1-methylazetidine-3-carboxamide
  参考文献：
  名称：

  WO2024008680A1

  摘要：

  公开号：

文献信息

• Unlocking Tertiary Acids for Metallaphotoredox C(sp²)–C(sp³) Decarboxylative Cross-Couplings
  作者：Junqing Guo、Derek Norris、Antonio Ramirez、Jack L. Sloane、Eric M. Simmons、Jacob M. Ganley、Martins S. Oderinde、T. G. Murali Dhar、Geraint H. M. Davies、Trevor C. Sherwood

  DOI：10.1021/acscatal.3c03353

  日期：2023.9.15

  Dual nickel photoredox catalysis conditions have been developed for the decarboxylative cross-coupling of aryl halides and carboxylic acids containing fully substituted α-carbons, a valuable but challenging substrate class for C(sp2)–C(sp3) bond-forming reactions. High-throughput experimentation identified Ni(TMHD)2 as the optimal precatalyst for this reaction in contrast to the nickel-bipyridyl complexes

  双镍光氧化还原催化条件已开发用于芳基卤化物和含有完全取代的 α-碳的羧酸的脱羧交叉偶联，这是 C(sp 2 )–C(sp 3 ) 键形成反应的有价值但具有挑战性的底物类别。高通量实验确定 Ni(TMHD) 2是该反应的最佳预催化剂，而脱羧偶联中通常使用的镍联吡啶络合物主要提供不需要的 C-O 产物。计算工作提供了对二酮酸镍配合物的 C-C 与 C-O 选择性的潜在机制基础的见解。
• WO2020131627A5
  申请人：——

  公开号：WO2020131627A5

  公开（公告）日：2022-12-20
• SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES
  申请人：Array Biopharma, Inc.

  公开号：EP3898626A1

  公开（公告）日：2021-10-27
• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES<br/>[FR] COMPOSÉS PYRAZOLO[1,5-A]PYRIDINE SUBSTITUÉS SERVANT D'INHIBITEURS DE TYROSINE KINASES FGFR
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2020131627A1

  公开（公告）日：2020-06-25

  Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which Ring A, Ring B, Ring C, R1, R2, L, Y, and W have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.
• [EN] 7-((3,5-DIMETHOXYPHENYL)AMINO)QUINOXALINE DERIVATIVES AS FGFR INHIBITORS FOR TREATING CANCER<br/>[FR] DÉRIVÉS DE 7-((3,5-DIMÉTHOXYPHÉNYL)AMINO)QUINOXALINE SERVANT D'INHIBITEURS DE FGFR POUR LE TRAITEMENT DU CANCER
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2020131674A1

  公开（公告）日：2020-06-25

  Provided herein are 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X 2 is N and Ring A, Ring B, Ring C, X 1, X 3, R 1, L, and W have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, such as e.g. cancer, e.g. bladder cancer, brain cancer, breast cancer, cholangiocarcinoma, head and neck cancer, lung cancer, multiple myeloma, rhabdomyosarcoma, urethral cancer and uterine cancer. The present description discloses the preparation of exemplary compounds as well as pharmacological data thereof (e.g. pages 276 to 308; examples 1 to 30; examples A to E; tables CA to EE). An exemplary compound is e.g. 1-(3-(4-(4-(7-((3,5-dimethoxy phenyl) amino)quinoxalin-2-yl)-1H-pyrazol-l-yl)piperidine-1-carbonyl) azetidin-1-yl)prop-2-en-1-one (e.g. example 1).